Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma (multiple letters) [3]

Journal of the National Cancer Institute

Volumn 95, Issue 15, 2003, Pages 1174-1175

  Tu, Shi Ming ^a   Lin, Sue Hwa ^a,b   Logothetis, Christopher ^a   Saad, Fred ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; PLACEBO; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; HORMONE RESISTANCE; HUMAN; LETTER; MALE; OSTEOPOROSIS; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; PROSTATE CARCINOMA; BONE TUMOR; CONTROLLED CLINICAL TRIAL; METABOLISM; METASTASIS; NOTE; PATHOLOGY; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; DIPHOSPHONATES; FRACTURES, SPONTANEOUS; HUMANS; IMIDAZOLES; MALE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0042209602     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djg020     Document Type: Letter

References (0)